Poxvirus Research Advances May Stay Stock Destruction

On Dec. 31, 1993, the last stores of the smallpox (variola) virus were to be destroyed simultaneously in Russia and the United States, according to an agreement arranged through the World Health Organization (WHO). If the agreement had been effected, it would have been the first intentional destruction of a human disease and its causative organism. The date has passed, however, and the stores remain intact. But researchers through

Written byMyrna Watanabe
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

On Dec. 31, 1993, the last stores of the smallpox (variola) virus were to be destroyed simultaneously in Russia and the United States, according to an agreement arranged through the World Health Organization (WHO). If the agreement had been effected, it would have been the first intentional destruction of a human disease and its causative organism. The date has passed, however, and the stores remain intact.

But researchers throughout the world who have been studying the orthopoxviruses--the array of poxviruses endemic to many animal species--and who have been clamoring for a five- to 10-year reprieve for variola for potential further study do not consider this a complete victory, since the fate of the virus is yet to be finally decided.

WHO's Committee on Orthopoxvirus Infections, which originally recommended the destruction of the smallpox virus, now is awaiting the completion of sequencing of the viral genome, being done at the Centers ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies